Suggestions for effective contraception in isotretinoin therapy

British Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2009, Pages 137-138

  Kanelleas, Antonios I ^a   Thornton, Steve ^b   Berth Jones, John ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; ISOTRETINOIN; MEDROXYPROGESTERONE ACETATE;

ACNE; CONTRACEPTION; DRUG EFFICACY; HEADACHE; HUMAN; LETTER; MENSTRUAL IRREGULARITY; OSTEOPOROSIS; PREGNANCY TEST; PRIORITY JOURNAL; SIDE EFFECT; TERATOGENICITY; TREATMENT PLANNING; UNWANTED PREGNANCY; WEIGHT GAIN;

ACNE VULGARIS; CONTRACEPTION; DERMATOLOGIC AGENTS; HUMANS; ISOTRETINOIN; PRACTICE GUIDELINES AS TOPIC; TERATOGENS;

EID: 58149117728     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03235.x     Document Type: Letter

References (6)

1. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007 63 : 196 205.
2. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995 333 : 101 6.
3. Mitchel AA, Van Bennekom CM, Louik C. An assessment of the Accutane (isotretinoin) Pregnancy Prevention Program. FDA Dermatologic Drugs Advisory Committee Meeting, Gaithersburgh, MD, September 18, 2000. Available at http://www.fda.gov/ohrms/dockets/ac/00/slides/3639s1i.ppt (last accessed 4 September 2001).
4. Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, Gollnick H, Layton AM, Leyden JJ, Mascaro JM, Ortonne JP, Shalita A. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997 194 : 351 7.
5. Committee for Proprietary Medicinal Products (CPMP). Committee for Proprietary Medicinal Products (CPMP) summary information on a referral opinion following an arbitration pursuant to Article 29 of Directive 2001/83/EC, for Isotretinoin/Lurantan/Trivane/Rexidal/Scheritonin (see Annex I). International Non-Proprietary Name (INN): Isotretinoin. London, 17 October 2003. CPMP/2811/03.
6. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008 77 : 67 76.